Target intelligence / Profile preview

B-cell lymphoma 6 transcription repressor (BCL6)

Target: BCL6
Molecular classification: Transcription factor, Zinc finger transcription factor, Transcriptional repressor, Structural features: BCL6 contains three evolutionarily conserved structural domains: (1) an N-terminal BTB/POZ domain (Broad-complex, Tramtrack and Brick-a-brac/Pox virus and Zinc finger family domain), (2) a central RN2 region, and (3) a C-terminal zinc finger domain. The protein encodes zinc finger domains that specifically bind DNA sequences.

Overview

BCL6 (B-cell lymphoma 6 transcription repressor) is a zinc finger transcription factor that functions as a master regulator of germinal center formation and T follicular helper cell differentiation. As a transcriptional repressor, BCL6 binds specific DNA sequences through its conserved zinc finger domains and recruits corepressors and histone deacetylases to regulate target gene expression. In normal physiology, BCL6 is essential for antibody affinity maturation and immune memory by allowing B-cells to undergo rapid proliferation and tolerate DNA breaks during somatic hypermutation without triggering apoptosis. However, BCL6 acts as a protooncogene; when constitutively expressed or mutated, it drives diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies by promoting unchecked cell proliferation. BCL6 is frequently translocated and hypermutated in lymphomas and serves as a diagnostic biomarker for B-cell lymphoma classification. Given its critical role in both normal immunity and lymphomagenesis, BCL6 has emerged as a promising therapeutic target for cancer treatment, with peptidomimetics, small molecules, and natural compounds in preclinical development showing anti-lymphoma activity.

Other names: B-Cell Lymphoma 6 ProteinB Cell CLL/Lymphoma 6Protein LAZ-3BCL-5Lymphoma-Associated Zinc Finger ProteinCys-His2 Zinc Finger Transcription FactorZinc Finger Transcription Factor BCL6S

Mechanism of action

Drug Targeting Strategies: Deletion of BCL6 in tumor cells is proposed as a therapeutic approach for cancer treatment. Targeting BCL6 should reduce its tumorigenic effects in B-cell lymphomas. Functional Mechanisms: BCL6 functions through multiple mechanisms, including: Direct transcriptional repression of gene promoters and enhancers, Subversion of AP1 (activator protein 1) activity through direct binding, Binding to DNA sequences recognized by the STAT (signal transducer and activator of transcription) family, and Formation of complexes with corepressors and histone deacetylases.

Biological functions

Germinal center formation and development: BCL6 is essential for germinal center (GC) formation and is required for B-cell proliferation in response to T-cell dependent antigens.Antibody affinity maturation: BCL6 is mainly required for antibody affinity maturation by allowing GC B-cells to tolerate physiological DNA breaks required for immunoglobulin class switch recombination and somatic hypermutation.T follicular helper cell differentiation: BCL6 is a master lineage-defining transcription factor for T follicular helper cell (T~FH~) differentiation and regulation.Immune response regulation: BCL6 modulates STAT-dependent interleukin-4 (IL-4) responses of B cells, suppresses Th2 responses and inflammatory processes, and regulates immune memory establishment.Transcriptional repression: BCL6 acts as a sequence-specific repressor of transcription, binding directly to the DNA sequence 5'-TTCCTAGAA-3' (BCL6-binding site) or indirectly by repressing transcription factor activity.Cell cycle control and apoptosis suppression: BCL6 prevents cell death (apoptosis) and controls cell cycle progression in GC B-cells in both p53-dependent and -independent manners.Macrophage regulation: BCL6 suppresses macrophage proliferation through competition with STAT5 for STAT-binding motifs on target genes.

Disease associations

Cancer (B-cell lymphomas): BCL6 is frequently translocated and hypermutated in diffuse large B-cell lymphoma (DLBCL) and contributes to pathogenesis. Mutations in BCL6 can lead to B-cell lymphomas by promoting unchecked B-cell growth. BCL6 is also associated with Intravascular Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma Double-Hit/Triple-Hit. BCL6 is exclusively present in B-cells of both healthy and neoplastic germinal centers, enabling lymphoma diagnosis through immunohistochemical staining for Burkitt's lymphoma, follicular lymphoma, and nodular lymphocyte predominant Hodgkin's disease.Disease Mechanism: Many genetic and epigenetic changes can lead to B-cell lymphomas through BCL6 dysfunction, including direct effects (mutation and post-translational effects) and indirect effects (imbalanced interactions with other mutated proteins).

Safety considerations

Risk of excessive immune suppression: Since BCL6 prevents apoptosis and controls immune responses, its inhibition could potentially trigger excessive cell death in normal GC B-cells or disrupt germinal center formation and antibody production.Balancing oncogenic and tumor-suppressive functions: BCL6 has dual roles—while it prevents lymphoma formation by silencing oncogenes in normal GC B-cells, unchecked BCL6 expression drives lymphoma development. Therapeutic targeting must distinguish between these contexts.Off-target immune effects: BCL6 regulates multiple immune cell types (B cells, T~FH~ cells, macrophages), and targeting it could have broad immunological consequences.Context-dependent function: BCL6 exhibits substantially cell context-dependent functions, meaning its effects differ between normal and malignant cells, requiring careful consideration of therapeutic specificity.

Interacting drugs

The search results do not identify specific FDA-approved drugs currently targeting BCL6. However, peptidomimetics, small molecules, and natural compounds have been developed and tested in preclinical models, showing promise of anti-lymphoma activity.

Biomarkers

Diagnostic Biomarker: BCL6 protein expression serves as a diagnostic marker for B-cell lymphomas. Clinically, BCL6 can be used to diagnose B-cell lymphomas and is shown to be upregulated in a number of cancers. Immunohistochemical staining revealing BCL6 presence enables diagnosis of specific lymphoma subtypes.Prognostic Significance: BCL6 is upregulated in multiple cancer types, with potential implications for patient stratification and treatment selection.

Beyond the preview

Go deeper on B-cell lymphoma 6 transcription repressor (BCL6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B-cell lymphoma 6 transcription repressor (BCL6).

Explore the full profile